Press Release

The targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030

The targeted protein

iCrowdNewswire   Mar 3, 2021  11:30 AM ET

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

  • Type of payment of licensing agreements
  • Upfront payments
  • Milestone payments
  • Type of protein degrader
  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders
  • Therapeutic area
  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas
  • Route of administration
  • Oral
  • Intravenous
  • Other routes
  • Key geographical region
  • North America
  • Europe
  • Asia-Pacific

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Arvinas
  • Captor Therapeutics
  • Celgene
  • Genetech
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Current Market Landscape
  5. Company Profiles
  6. Clinical Trial Analysis
  7. KOL Analysis
  8. Publication Analysis
  9. Funding and Investment Analysis
  10. Partnerships and Collaborations
  11. Market Sizing and Opportunity Analysis
  12. Executive Insights
  13. Concluding Remarks
  14. Appendix 1: Tabulated Data
  15. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

Contact Information:

Contact:
Gaurav Chaudhary
[email protected]

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
[email protected]
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis


iCrowdNewswire

Keywords:    Protein degradation, Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, PROTACs, Roots Analysis, Research, Biotech, Pharma, Analysis, Report, Market Report, Market Analysis